HC Wainwright & Co. Reiterates Buy on Coya Therapeutics, Maintains $18 Price Target
Coya Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
Coya Therapeutics Q3 EPS $(0.45) Misses $(0.34) Estimate, Sales $234.134K Beat $85.714K Estimate
Coya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual NEALS Meeting
Coya Therapeutics To Highlight ALS Data In Poster Presentation At 2026 Annual NEALS Meeting; Co. Currently Conducts ALSTARS Trial, Phase 2/3, Study To Evaluate COYA 302 For ALS Treatment
Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS
Coya Therapeutics Plans To Initiate Open-Label Extension Of Phase 2/3 ALSTARS Trial Evaluating COYA 302 For Treatment Of Amyotrophic Lateral Sclerosis
Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference
Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
Coya Therapeutics Announces Full Enrollment Of Planned 120 Participants In Phase 2/3 ALSTARS Trial Evaluating COYA 302 For Potential Treatment Of Amyotrophic Lateral Sclerosis
BTIG Reiterates Buy on Coya Therapeutics, Maintains $16 Price Target
Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
Coya Therapeutics Enrolls 100th Participant In Phase 2/3 ALSTARS Trial Of COYA 302
Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation
Coya Therapeutics Announces Publication Of Preclinical Results For COYA 303 In International Journal Of Molecular Sciences; Results Show Complementary Immunomodulatory Effects In Peripheral And CNS Inflammation
Roth Capital Reiterates Buy on Coya Therapeutics, Maintains $12 Price Target
Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Coya Therapeutics Q2 EPS $(0.28) Beats $(0.34) Estimate, Sales $243.745K Beat $100.000K Estimate
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
Coya Therapeutics To Present Overview Of Ongoing ALSTARS Trial At European Network To Cure ALS June 24-26
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.